What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce the issuance of a press release containing preliminary results from a Phase 2 clinical study of aflibercept (VEGF Trap) in advanced ovarian cancer patients.

What is aflibercept (VEGF Trap) and what condition is it being studied for?

Aflibercept, also referred to as VEGF Trap, is a drug candidate being investigated by Regeneron and sanofi-aventis. This specific study evaluated its efficacy in patients with advanced ovarian cancer who have recurrent symptomatic malignant ascites.

What were the preliminary results of the study?

The 8-K filing itself does not disclose the specific preliminary results. It only announces that a press release containing these results has been issued. Investors would need to refer to the press release (Exhibit 99.1) for the detailed outcomes.

What is the significance of this study for Regeneron investors?

This study represents progress in the clinical development of aflibercept, a potentially important drug candidate. The preliminary results, once reviewed in the press release, could provide insights into the drug's potential and future development path, particularly in oncology indications, and highlight the strength of the Regeneron-sanofi-aventis collaboration.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 11, 2009, to announce the issuance of a press release detailing preliminary results from a Phase 2 study. This study evaluated aflibercept (VEGF Trap) in patients with advanced ovarian cancer experiencing recurrent symptomatic malignant ascites. The study was randomized and placebo-controlled, conducted in collaboration with sanofi-aventis.

Key Highlights

1Regeneron, in partnership with sanofi-aventis, announced preliminary Phase 2 study results for aflibercept.
2The study focused on advanced ovarian cancer patients with recurrent symptomatic malignant ascites.
3Aflibercept, also known as VEGF Trap, was the drug candidate investigated.
4The study design was a randomized, placebo-controlled trial.
5The press release providing these preliminary results is attached as an exhibit to the 8-K filing.
6This filing indicates ongoing clinical development and data reporting for a key pipeline asset.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Jun 11, 2009)

Summary

Key Highlights

Frequently Asked Questions